Christopher Viehbacher on earnings guidance
From Biogen Inc ($BIIB) Q1 2025 Earnings Call · · Castify Earnings Call
“We now expect our full year 2025 non-GAAP diluted earnings per share to be between $14.50 and $15.50. We continue to expect total revenue for 2025 to decline by a mid single-digit percentage driven primarily by an increased decline in our MS business. We expect that our launch products will generate sequential revenue growth, but we expect the absolute MS revenue decline to be steeper than this growth in 2025.”
On , Christopher Viehbacher, President, Chief Executive Officer & Director at Biogen, spoke about earnings guidance during Biogen Inc ($BIIB) Q1 2025 Earnings Call on Castify Earnings Call.
About Christopher Viehbacher
On Biogen's first quarter 2025 earnings call, Christopher Viehbacher described the company as "a tale of two companies," noting that its multiple sclerosis portfolio has been "gradually declining" while a "new Biogen" is emerging. He stated that the company's actively promoted commercial portfolio, including rare disease drugs and Alzheimer's treatments, now accounts for about 45% of product revenue. Viehbacher called Leqembi "the first disease modifying agent that has ever been approved in Alzheimer's" and said that having regulatory endorsement is "extremely important." Viehbacher said Biogen does not expect a material impact in 2025 from potential tariffs, even if the pharmaceutical exemption were removed, citing U.S.-based manufacturing and global inventory positions. He noted that Biogen is open to partnering on excess manufacturing capacity, mentioning that its Solothurn facility is doing contract development and manufacturing organization (CDMO) business and that its Research Triangle Park facility already manufactures for third parties. He also stated that Biogen has a goal of signing four to five new research collaborations in 2025.